Company PresentationFebruary, 2018 Ofer Haviv, President & CEO

Safe Harbor Statement 2 This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “intend” and “potential” or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading “Risk Factors.” All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

What We Do 3 We develop novel products for life-science markets… …through the use of a unique Computational Predictive Biology (CPB) platform

Evogene at a Glance… 4 Commercial Partners Improved Seeds InnovativeAg-Chemicals NovelAg-Biologicals Geneticelements Microbes Chemical compounds CPB An innovative, Computationally Predictive Biology (CPB) platform - applied to identify:Genetic elements for improved seedsChemical compounds for innovative Ag-ChemicalsMicrobes for novel Ag-BiologicalsStrategic collaborations with world-leading agriculture companies - including BASF, DuPont, Monsanto, Syngenta, ICLRevenue model - based on licensing agreements, which typically include three main revenue streams:R&D payments - short termMilestone payments - mid termRoyalties from product sales - longer termSubsidiaries -Evofuel (100%) - Castor Seeds Biomica (90%) - Human MicrobiomeFinancial fundamentals -Cash position - $76 million (September 30th, 2017), no debtListed on TASE (2007) and NASDAQ (2013)

Strategic Collaborations Through the Years 5

Evogene – An Evolving Story 6 Seed TraitsYield & ABSTPlant Disease EvofuelCastor Seeds (100%) CPB IPO TASE - IPO NYSE2007-2013 GMO, Breeding

Evogene – An Evolving Story 7 Ag BiologicalsBio Stimulants (100%) CPB Seed TraitsYield & ABSTPlant DiseaseInsect Control EvofuelCastor Seeds IPO NYSE – Sep 20172013-2017 GMO, Breeding Ag ChemicalsHerbicidesInsecticides

Evogene – An Evolving Story 8 BiomicaHuman Microbiome based Therapeutics (100%) (90%) CPB GMO, Breeding,Genome Editing Seed TraitsYield & ABSTPlant DiseaseInsect Control EvofuelCastor Seeds Ag ChemicalsHerbicidesInsecticides Ag BiologicalsBio StimulantsBio Pesticides Sep 2017 - Onward2017 - Onward

Corporate Structure 9 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)

Evogene’s Unique Product Development Approach 10 Product Definition Successful Product Launch … Evogene takes product criteria into account at Stage Zerofocusing only on optimal product candidates The increasing number of criteria for successful product launch have made traditional linear methodology inefficient Efficacy Stability Shelf-life Safety Increasing probability of successReducing time to marketReducing budget

Computational Predictive Biology (CPB) Platform Interconnected data hub Science: unique multidisciplinary scientific approach Tailored big data Analysis platforms using machine learning/AI to identify candidates Chemical discovery Stack discovery Target discovery Gene discovery Gene optimization Toxin discovery Microbial Discover/ Optimization 150K 20K 150K 15K Predictive analysis validation & product development The CPB platform -‘Connecting the Dots’

12 Predictive Analysis Validation

13 Product Development

Corporate Structure 14 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)

Existing Biotech Traits Market Potential Biotech Traits Market Insect resistance Herbicide tolerance Yield Drought tolerance Disease resistance Corn $3.2B $3.5B $1.5B $0.65B $1B Soy $0.5B $1.5B $1.2B $0.45B $1B Ag Seeds - Market & Potential 15 Biotech Innovation Trait Potential * Source: Phillips McDougall ~$37B*Seeds Market(2016) Trait Corn Soy Existing Biotech Traits Market Insect resistance $3.2B $0.5B Herbicide tolerance $3.5B $1.5B Potential Biotech Traits Market Yield $1.5B $1.2B Drought tolerance $0.65B $0.45B Disease resistance $1B $1B

16 Ag Seeds – Product & Technology Stability Safety Via: Breeding, Genome Editing & GMO Improved Seed Traits The CPB platform - ‘Connecting the Dots’ Environment Efficacy The CPB platform - ‘Connecting the Dots’ Yield and environmental stress traits- Yield, drought, nitrogen usage efficiencyDisease resistance traits- Fusarium, Black Sigatoka, Asian Rust, Nematodes Insect control traits- Lepidoptera, Coleoptera, Hemiptera Products under development:

Genome Editing – New Promising Technology 17 Evogene’s unique advantage – ‘What to edit’Technological capabilities, knowledge and proprietary plant genomics big data, allow the identification of required edit-targets for crop improvement Novel method for improving seed traitsResulting products may be considered Non-GMO with shorter time to marketMajor opportunity for all crops and locations

Corn Yield Drought Nitrogen use efficiency Fusarium stalk rot Insect control Coleop. Insect control Lepido. Soybean Yield Drought Asian Rust Insect control Lepido. Insect control Hemip. Cotton Insect control Lepido. Banana Black Sigatoka Ag Seeds Pipeline (main programs) Discovery Phase 1 (POC) Phase IV (Pre -Launch) 18m-24m 1-2 years Phase 2 (Early Development) Phase 3 (Adv. Dev & Regulation) 1-2 years 4-6 year 2-4 year Crop Trait Partner Discovery Phase 1 (Creation of Edits) 6m-12m Phase 2 (Field Testing) Phase 3 (Seed Production) 1-2 year Crop Partner 3-4 years 1-2 year Product Product Main GMO programs* 18 Main Genome-Editing programs* Trait Banana Black Sigatoka Soybean Yield Soybean Nematode *Timeline according to industry estimates *Timeline according to industry estimates

Select Results - Black Sigatoka 19 8 Genes showed repeated increased resistance in two separate banana field trialsPositive results were observed with zero fumigationLeveraging validated genes with positive results to genome editing product development Banana with high resistance to the Black Sigatoka fungus showing positive results (Y2014, Y2016)

Biologicals Corporate Structure 20 Ag Divisions Seeds Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)

21 Ag Biologicals Market & Potential ~$8B ~$3.2B Source – 2022 estimation based on integrated information of BCC Research, marketsandmarkets, Agropages and Phillips McDougall (2015) 2022 E Key market drivers Major Ag companies are getting in: New startups are emerging: Bio-Stimulants - 38% Bio-Pesticides - 62% Ag-Biologicals Market ~$3.2B*2015 Ag Biologicals Innovation Potential - Development of “next generation” products Microbiome a promising source for innovation, now accessible via maturing technologiesRelatively short time and low investment to marketEnvironmentally friendly

The CPB platform - ‘Connecting the Dots’ Ag-Biologicals – Product & Technology 22 Plant Pest Microbiome(plant/ pest) Bio-Stimulants & Bio-Pesticides Harnessing naturally occurring microbiome to develop:Bio-Stimulant seed treatments – targeting yield improvement in row crops such as corn, wheatBio-Pesticides – corn root worm, stinkbug, lepidoptera Bio- Fungicides - targeting fusarium and mildew Products under development:

Ag-Biologicals Pipeline 23 Discovery Early development Pre-Commercialization Bio Stimulants Corn Wheat Bio Pesticides Corn Root Worm Stinkbug (Soy) Lepidoptera(Specialty) Bio Fungicide Fusarium (Corn) Mildew (Grapes) Development 1 Development 2 Program Product *Timeline according to industry estimates ~ 6-8 years*

Select Results – Corn Bio-Stimulants 24 None - inoculated EVO004 Stem below ear R2 Stem below ear R2 Ear R3 Ear R3 14 1 16 1 Under moderate drought 10% Yield improvement in field trials (2016, 2017)

Corporate Structure 25 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)

Ag-Chemicals - Market & Potential 26 Increasing weed resistance to leading herbicide - Glyphosate 2015 Source: Phillips McDougall** Sources: ‘Phillips McDougall’ and ‘Markets and Markets’, 2017 Insecticides Fungicides Herbicides Other ~$50B*Agro-Chemical Market(2016) Agro-Chemical Marketexpected to reach ~$70B in 2022** Key market drivers Food Security - necessity of Ag-Chemicals in light of growing resistance issues (crop protection Ag-Chemicals account for ~50% of key crop yield)Novel MoA Ag-Chemicals - due to increasing pest resistance to existing products Environmentally safe Ag-Chemicals - strong regulatory emphasis on safety Innovation Potential – finding the next generation of novel Ag-Chemicals Source - International Survey of Herbicide Resistant Weeds, www.weedscience.org/graphs/soagraph.aspx (2013)

The CPB platform - ‘Connecting the Dots’ Herbicides & Insecticides Ag-Chemicals – Product & Technology 27 Delivery Chemistry Herbicides & Insecticides Plant/Insect Biology Novel Herbicides - inhibiting novel MoA (Mode-of-Action) Novel Insecticides - inhibiting novel SoA (Site-of-Action) within key nerve and muscle targetsOptimized Active Ingredient (AI) Herbicides/Insecticides - optimization of known chemicals to improve product attributes Products under development:

Ag-Chemicals Pipeline 28 2-3 yearsDiscovery 3-4 yearsPre-development 3-4 yearsDevelopment & Registration Herbicides Novel herbicides AI optimization New targets Novel herbicides Phase undisclosed Insecticides New SoA Program Target identification Computational Screen Hit Validation Hit-to-Lead Lead Optimization AI-Active IngredientSoA- Site-of-ActionMoA- Mode-of-ActionTarget- Vital functions in pestsHit- Chemical compound discovered to impact a target Lead- optimal product candidate Development & registration Product *Timeline according to industry estimates

Select Results – Novel Herbicides 29 Dosage Molecule Optimization Molecule Example of Efficacy Optimization of Chemical Compounds on Weeds (Y 2017) *Initial results before optimization Example for Chemical Compound - Displaying Herbicidal Activity in Greenhouse

Corporate Structure 30 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)

Evofuel 31 Mission: providing farmers with the most advanced castor seeds & ag-service solutions Evofuel targets South America Genomics & Technology- advanced breeding and varietiesSeed production- Castor bean fields for the production of seedsAgro-technical support- Market specific crop protocolsMechanical harvesting solution support Activities

Biomica 32 Sources: BCC Research (2017) – Human Microbiome-based Drugs and Diagnostics Market. SVB – (Emerging Healthcare: Microbiome Investment Trends Aug 2017) ~$ 10Bn market opportunity by 2024 Mission: discovery and development of human microbiome based therapeutics $840M invested in microbiome space since 2010 Big pharma and VCs deeply engaged Human Microbiome Based Drugs Market Evogene’s computational predictive biology (CPB) platform enables multi-layer analysis for the discovery of highly efficacious therapeutic candidates and relevant microbiome-based biomarkersInitiated in 2017, Biomica represents Evogene’s first effort to apply its predictive discovery capabilities in the field of human health. Activities

Corporate Structure 33 Ag Divisions Seeds Biologicals Chemicals Subsidiaries Computational Predictive Biology Platform (CPB)

Evogene Highlights 5 2 3 4 Strong balance sheet 1 Engine for next generation product for life science - targeting multi-billion dollar markets Unique technology platform (CPB), combining expertise in life science and cutting-edge computational technology – ‘Connecting the Dots’ Diversified product portfolio with clear paths to milestone payments and royalties Innovation partner-of-choice for industry leaders 34 Short term catalysts: (i) collaborations, (ii) phase advancements, (iii) milestone payments, (iv) Evofuel seed sales 6

Thank You Contact:investors@evogene.comT: +972 8 931 1934

36 Appendix - Financials

Key Financials – Balance Sheet 37 Thousand US $ 30.9.2017 31.12.2016 Current Assets 77,842 89,490 Long-Term Assets 5,263 6,496 Total Assets 83,105 95,986 Current Liabilities 4,661 5,225 Long-Term Liabilities 3,439 3,472 Shareholders Equity 75,005 87,289 Total Liabilities & Shareholders Equity 83,105 95,986 Key Points: Cash position: ~76 million USD as of 30.9.2017 No debtEstimated net cash usage for 2018: $14-$16 million

Key Financials – P&L 38 Thousand US $ 9M 2017 9M 2016 2016 Revenues 2,647 5,360 6,540 Gross Profit 436 852 901 Operating Loss (15,928) (14,937) (21,089) Net Loss (14,614) (12,949) (19,592) Key Points: Revenues consist primarily of R&D revenues, reflecting cost reimbursement under our collaboration agreementsAdvancement of our collaboration agreement with Monsanto reducing R&D revenues